Leaderboards/Neuroendocrine Tumor Research Advances

Neuroendocrine Tumor Research Advances

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Lacey Padrón
Parker Institute for Cancer Immunotherapy
2
Taymeyah Al‐Toubah
Moffitt Cancer Center
3
Mengqing Xie
Tongji University
4
Abbie S. Ireland
Duke University
5
Meilin Xue
City of Hope
6
Abdelrahman Yousef
University of New Mexico Hospital
7
Rishav Adhikari
Stanford University
8
Jacopo Millul
University Hospital of Basel
9
Abhishek Ajay
University Hospitals Seidman Cancer Center
10
Philipp Melhorn
Medical University of Vienna

Papers

1
Publication in npj Precision Oncology (2024) [82 citations, W4391514138]
npj Precision Oncology|2024
82 cit.
2
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation
Journal of Hematology & Oncology|2024
79 cit.
3
Publication in JAMA Network Open (2024) [30 citations, W4392231659]
JAMA Network Open|2024
30 cit.
4
Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
ESMO Open|2024
19 cit.
5
Enhanced contrast in FAP-targeting PET imaging with 61Cu-labeled FAP inhibitors: development and preclinical evaluation of novel [61Cu]Cu-Kalios PET radioligands
EJNMMI Radiopharmacy and Chemistry|2025
3 cit.
6
Do Appendiceal Neuroendocrine Tumors Metastasize Post Appendectomy or Right Hemicolectomy?
Journal of the National Comprehensive Cancer Network|2024
2 cit.
7
Publication in Cancer Research (2024) [1 citation, W4390915351]
Cancer Research|2024
1 cit.
8
Publication in Annals of Oncology (2024) [W4400151601]
Annals of Oncology|2024
0 cit.
9
Publication in Journal of Neuroendocrinology (2025) [W4406811115]
Journal of Neuroendocrinology|2025
0 cit.
10
Publication in Endocrine Abstracts (2025) [W4408332005]
Endocrine Abstracts|2025
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Cindy Hochstetler
National Comprehensive Cancer Network
2
Lynnette Fernandez‐Cuesta
Centre international de recherche sur le cancer
3
Jennifer A. Chan
Dana-Farber Cancer Institute
4
Griselda Zuccarino-Catania
Pancreatic Cancer Action Network
5
Jianguo Sun
Army Medical University
6
Lauren Fishbein
University of Colorado Cancer Center
7
Xavier M. Keutgen
University of Chicago
8
Jie Zhang
Indiana University – Purdue University Indianapolis
9
Jonathan Gear
Institute of Cancer Research
10
Huanhuan Sun
Shanghai Jiao Tong University

Papers

1
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
European Journal of Nuclear Medicine and Molecular Imaging|2022
234 cit.
2
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023
Journal of the National Comprehensive Cancer Network|2023
206 cit.
3
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022
Journal of the National Comprehensive Cancer Network|2022
125 cit.
4
Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity
Nature Genetics|2023
83 cit.
5
EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials
European Journal of Nuclear Medicine and Molecular Imaging|2024
45 cit.
6
NCAPG promotes the oncogenesis and progression of non-small cell lung cancer cells through upregulating LGALS1 expression
Molecular Cancer|2022
44 cit.
7
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms
Endocrine Related Cancer|2023
42 cit.
8
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network|2025
30 cit.
9
A machine-learning algorithm for distinguishing malignant from benign indeterminate thyroid nodules using ultrasound radiomic features
Journal of Medical Imaging|2022
23 cit.
10
EANM enabling guide: how to improve the accessibility of clinical dosimetry
European Journal of Nuclear Medicine and Molecular Imaging|2023
22 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Robert T. Jensen
National Institutes of Health
2
Eric P. Krenning
Cyclotron (Netherlands)
3
James C. Yao
The University of Texas MD Anderson Cancer Center
4
Kjell Öberg
Uppsala University Hospital
5
Philippe Ruszniewski
Inserm
6
Günter Klöppel
Technical University of Munich
7
Ralph H. Hruban
Johns Hopkins University
8
Bertram Wiedenmann
Charité - Universitätsmedizin Berlin
9
David S. Klimstra
Yale University
10
Mark Kidd
Wren Laboratories (United States)

Papers

1
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
JAMA Oncology|2017
3.5k cit.
2
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
New England Journal of Medicine|2017
3.2k cit.
3
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
New England Journal of Medicine|2011
2.8k cit.
4
A 5‐decade analysis of 13,715 carcinoid tumors
Cancer|2003
2.7k cit.
5
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
New England Journal of Medicine|2011
2.5k cit.
6
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
New England Journal of Medicine|2014
1.9k cit.
7
The Digital Provide: Information (Technology), Market Performance, and Welfare in the South Indian Fisheries Sector
The Quarterly Journal of Economics|2007
1.9k cit.
8
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
Journal of Clinical Oncology|2008
1.4k cit.
9
Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles
Cell|1985
1.4k cit.
10
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
The Lancet|2015
1.3k cit.

Reagents for Neuroendocrine Tumor Research Advances

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Agilent/Dako

Polyclonal Rabbit Anti-Human Chromogranin A

Cited in 8 papers
#A0430
View Evidence →
Agilent/DakoEvidence 60

Monoclonal Mouse Anti-Human Ki-67 Antigen, Clone MIB-1

Cited in 5 papers
#M7240
View Evidence →
Cell Signaling Technology

Vemurafenib

Cited in 5 papers
#17531$66
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 67

COL3A1 Antibody

Cited in 13 papers
#30565$317
View Evidence →
Agilent/Dako

Chromogranin-A (CHGA)

Cited in 12 papers
#M0869
View Evidence →
BD Biosciences

MASH1

Cited in 9 papers
#556604
View Evidence →